Real-World palbociclib use under the microscope in sweden

NCT ID NCT04654208

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 1,500 Swedish patients with metastatic breast cancer who are taking palbociclib as part of their treatment. Researchers want to see how long patients stay on the drug, what their characteristics are, and how they fare over time. It's an observational study, meaning it just watches what happens in real-world clinics without assigning treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: palbociclib
What this could lead to: If successful, this study could provide real-world insights into how palbociclib is used and how patients respond, potentially improving treatment guidelines.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by factors like patient selection or data completeness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM OF BREAST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM OF BREAST

Contacts and locations

Locations

Pfizer Sweden
RECRUITING

Sollentuna, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.